# Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors

> **NCT00880308** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 103 (actual)

## Conditions studied

- Advanced Solid Tumor Cancers
- Medulloblastoma
- Basal Cell Carcinoma

## Interventions

- **DRUG:** LDE225

## Key facts

- **NCT ID:** NCT00880308
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00880308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00880308, "Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00880308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*